Table 1.
Randomized Controlled Trials of DBS for Depression
| Study | N | Target | Stimulation Settings | Responder Criteria | Remission Criteria | At End of Trial Responders | Remitters | Primary Study Endpoint Met? | |
|---|---|---|---|---|---|---|---|---|
| Subcallosal Cingulate (SCC) (Holtzheimer et al. 2017) | 90 | SCG | 130 Hz | ≥ 40% reduction in MADRS from baseline | MADRS ≤ 10 |
Control Group: 5 (17%) Treatment Group: 12 (20%) |
Control Group:2 (7%) Treatment Group:3 (5%) |
No |
| Internal Capsule (VC/VS) (Dougherty et al. 2015) | 30 | VC/VS | Variable, primarily 130 Hz | ≥ 50% reduction on MADRS from baseline | Not assessed |
Control Group: 3 (20%)
Treatment Group: 2 (14.3%) |
N/A | No |
| (Bergfeld et al. 2016) | 25 | vALIC | 130 Hz–180 Hz | ≥50% reduction of the HAM-D-17 score compared with baseline | Not assessed | 10 (40%) | N/A | Yes |
| Medial Forebrain Bundle (MFB) (Fenoy et al. 2016) | 4 (Ongoing) | MFB | 130 Hz | 50% improvement on MADRS | Not assessed | 3 (75%) | N/A | Ongoing |
| (Coenen et al. 2019) | 16 | siMFB | 130 Hz | ≥ 50% reduction in MADRS | MADRS < 10 | 16 (100%) | 8 (50%) | No |